Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis

Canadian Journal of Cardiology

Volumn 28, Issue 5, 2012, Pages 574-580

  Lemstra, Mark ^a   Blackburn, David ^a   Crawley, Alex ^a   Fung, Ryan ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DRUG COST; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LOWEST INCOME GROUP; META ANALYSIS; PATIENT COMPLIANCE; PRIMARY PREVENTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT REFUSAL;

CARDIOVASCULAR DISEASES; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MEDICATION ADHERENCE; NEEDS ASSESSMENT; PATIENT COMPLIANCE; RISK ASSESSMENT; SASKATCHEWAN;

EID: 84866371890     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.05.007     Document Type: Review

References (87)

1. Haynes R.B., Yao X., Degani A., Kripalani S., Garg A., McDonald H.P. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2005, 4. CD000011.
2. Rasmussen J.N., Chong A., Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186.
3. May C., Montori V., Mair F. We need minimally disruptive medicine. BMJ 2009, 339:485-487.
4. Ting H.H., Shojania K.G., Montori V.M., Bradley E.H. Quality improvement: science and action. Circulation 2009, 119:1962-1974.
5. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
6. Schedlbauer A., Davies P., Fayey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010, 3. CD004371.
7. Mann D.M., Woodward M., Muntner P., Falzon L., Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010, 44:1410-1421.
8. Verhagen A.P., de Vet H.C.W., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemio1 1998, 51:1235-1241.
9. Sanderson S., Tatt I.D., Higgins J.P. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007, 36:666-676.
10. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2:121-145.
11. Lemstra M., Bennett N., Neudorf C., et al. A meta-analysis of school based marijuana and alcohol prevention programs in targeting adolescents aged 10-15 years old. Addict & Res Theory 2010, 18:84-96.
12. Lemstra M., Bennett N., Neudorf C., et al. A systematic review of drug and alcohol use by socioeconomic status in adolescents aged 10-15 years. Can J Public Health 2008, 99:172-177.
13. Lemstra M., Neudorf C., D'Arcy C., Kunst A., Warren L., Bennett N. A systematic review of depressed mood and anxiety by socioeconomic status in adolescents aged 10-15 years. Can J Public Health 2008, 99:125-129.
14. Abraha I., Montedori A., Stracci F., Rossi M., Romagnoli C. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003, 59:659-661.
15. Abughosh S.M., Kogut S.J., Andrade S.E., Larrat P., Gurwitz J.H. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manage Care Pharm 2004, 10:404-411.
16. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458-1462.
17. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
18. Benner J.S., Tierce J.C., Ballantyne C.M., et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004, 22(suppl 3):13-23.
19. Blackburn D.F., Dobson R.T., Blackburn J.L., Wilson T.W. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005, 25:1035-1043.
20. Bouchard M.H., Dragomir A., Blais L., Berard A., Pilon D., Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007, 63:698-708.
21. Brookhart M.A., Patrick A.R., Schneeweiss S., et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007, 167:847-852.
22. Bushnell C.D., Zimmer L.O., Pan W., et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol 2010, 67:1456-1463.
23. Caspard H., Chan A.K., Walker A.M. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005, 27:1639-1646.
24. Chan D.C., Shrank W.H., Cutler D., et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010, 48:196-202.
25. Charles H., Good C.B., Hanusa B.H., Chang C.C., Whittle J. Racial differences in adherence to cardiac medications. J Natl Med Assoc 2003, 95:17-27.
26. Chodick G., Shalev V., Gerber Y., et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008, 30:2167-2179.
27. Choudhry N.K., Brennan T., Toscano M., et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J 2008, 156:31-36.
28. Coberley C., Morrow G., McGinnis M., et al. Increased adherence to cardiac standards of care during participation in cardiac disease management programs. Dis Manage 2008, 11:111-118.
29. Donnelly L.A., Doney A.S., Morris A.D., Palmer C.N., Donnan P.T. Long-term adherence to statin treatment in diabetes. Diabet Med 2008, 25:850-855.
30. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004, 19:638-645.
31. Evans C.D., Eurich D.T., Lamb D.A., et al. Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manage Care Pharm 2009, 15:476-484.
32. Gislason G.H., Rasmussen J., Abildstrøm S., et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006, 27:1153-1158.
33. Ho P.M., Magid D.J., Masoudi F.A., McClure D.L., Rumsfeld J.S. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006, 6:48.
34. Hoeks S.E., Scholte op Reimer W.J., van Gestel Y.R., et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2009, 2:338-343.
35. Hudson M., Rahme E., Richard H., Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007, 153:59-65.
36. Hudson M., Richard H., Pilote L. Parabolas of medication use and discontinuation after myocardial infarction-are we closing the treatment gap?. Pharmacoepidemiol Drug Saf 2007, 16:773-785.
37. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462-467.
38. Kamal-Bahl S.J., Burke T., Watson D., Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007, 99:530-534.
39. Kopjar B., Sales A.E., Pineros S.L., Sun H., Li Y.F., Hedeen A.N. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003, 92:1106-1108.
40. Lachaine J., Rinfret S., Merikle E.P., Tarride J.E. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 2006, 152:164-169.
41. Larsen J., Andersen M., Kragstrup J., Gram L.F. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002, 53:375-378.
42. McGinnis B.D., Olson K.L., Delate T.M., Stolcpart R.S. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care 2009, 15:689-695.
43. Penning-van Beest F.J., Termorshuizen F., Goettsch W.G., Klungel O.H., Kastelein J.J., Herings R.M. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007, 28:154-159.
44. Perreault S., Blais L., Dragomir A., et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005, 61:667-674.
45. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005, 59:564-573.
46. Samant N.D. Clinical and Economic Impact of Statin Therapy Compliance on Hyperlipidemic Patients With Concomitant CHD Risk Factors [dissertation] 2010, University of Maryland School of Pharmacy, Baltimore.
47. Schneeweiss S., Patrick A.R., Maclure M., Dormuth C.R., Glynn R.J. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007, 115:2128-2135.
48. Shah N.D., Dunlay S.M., Ting H.H., et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009, 122:e7-e13.
49. Simpson R.J., Signorovitch J., Birnbaum H., et al. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc 2009, 84:1065-1072.
50. Smith C.S., Cannon C.P., McCabe C.H., Murphy S.A., Bentley J., Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J 2005, 149:444-450.
51. Tuppin P., Neumann A., Danchin N., et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010, 103:363-375.
52. Valuck R.J., Williams S.A., MacArthur M., et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003, 25:2936-2957.
53. Vanelli M., Pedan A., Liu N., Hoar J., Messier D., Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther 2009, 31:2628-2652.
54. Wei L., Fahey T., MacDonald T.M. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008, 66:110-116.
55. Wei L., MacDonald T.M., Watson A.D., Murphy M.J. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007, 16:385-392.
56. Wei L., Wang J., Thompson P., Wong S., Struthers A.D., MacDonald T.M. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002, 88:229-233.
57. Winkelmayer W.C., Levin R., Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol 2008, 3:1415-1422.
58. Ye X., Gross C.R., Schommer J., Cline R., St Peter W.L. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007, 29:2748-2757.
59. Eagle K.A., Kline-Rogers E., Goodman S.G., et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004, 117:73-81.
60. Glader E.L., Sjolander M., Eriksson M., Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010, 41:397-401.
61. Kalia N.K., Miller L.G., Nasir K., Blumenthal R.S., Agrawal N., Budoff M.J. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 2006, 185:394-399.
62. Mann D.M., Allegrante J.P., Natarajan S., Halm E.A., Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007, 21:311-316.
63. Melloni C., Alexander K.P., Ou F.S., et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009, 104:175-181.
64. Muhlestein J.B., Horne B.D., Bair T.L., et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001, 87:257-261.
65. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002, 105:2341-2346.
66. Collins R., Armitage J., Parish S., Sleight P., Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767. Heart Protection Study Collaborative G.
67. Dart A., Jerums G., Nicholson G., et al. A multi-center, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997, 80:39-44.
68. Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001, 87:1074-1079.
69. Guthrie R.M. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clin Ther 2001, 23:970-980.
70. Margolis K.L., Dunn K., Simpson L.M., et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT). Am Heart J 2009, 158:948-955.
71. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
72. Pedersen T.R., Berg K., Cook T.J., et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996, 156:2085-2092.
73. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [erratum appears in JAMA 2005;294:3092]. JAMA 2005, 294:2437-2445. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.
74. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996, 335:1001-1009.
75. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758-1764.
76. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM 1995, 333:1301-1307.
77. Stacy J.N., Schwartz S.M., Ershoff D., Shreve M.S. Incorporating tailored interactive patient solutions using interactive voice response technology to improve statin adherence: results of a randomized clinical trial in a managed care setting. Popul Health Manag 2009, 12:241-254.
78. Tikkanen M.J., Holme I., Cater N.B., et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged < 65 versus ≥ 65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 2009, 103:577-582.
79. Tonelli M., Moye L., Sacks F.M., Kiberd B., Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
80. Law M., Cheng L., Dhalla I., Heard D., Morgan S. The effect of cost on adherence to prescription medications in Canada. CMAJ 2012, 184:297-302.
81. O'Malley A.S., Forrest C.B., Mandelblatt J. Adherence of low-income women to cancer screening recommendations. J Gen Intern Med 2002, 17:144-154.
82. Celano M., Geller R.J., Phillips K.M., Ziman R. Treatment adherence among low-income children with asthma. J Pediatr Psychol 1998, 23:345-349.
83. Orlandi M.A. Promoting health and preventing disease in health care settings: an analysis of barriers. Prev Med 1987, 16:119-130.
84. Sewitch M.J., Abrahamowicz M., Barkun A., et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003, 98:1535-1544.
85. Glanz K., Rimer B., Viswanath K. Health Behavior and Health Education 2008, Jossey-Bass, San Francisco, CA. 4th ed.
86. Vik S.A., Maxwell D.J., Hogan D.B. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004, 353:487-497.
87. Grover S., Coupal L., Kouache M., Lowensteyn I., Marchand S., Campbell N. Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: the MyHealthCheckup Survey. Can J Cardiol 2011, 27:159-166.